Press releaseGlobe Newswire
Oramed Pharmaceuticals
ORMP · NASDAQ
$4.15+$0.09 (+2.22%)TodayMarket closed ·
Prev close $4.06
Latest news
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releasePRNewswire
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
- Press releasePRNewswire
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
- Press releaseGlobe Newswire
Lifeward Successfully Closes on Strategic Partnership with Oramed
- Press releaseGlobe Newswire
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
- Press releaseGlobe Newswire
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
- Press releasePRNewswire
Oramed and Lifeward Announce Strategic Transaction
- Press releasePRNewswire
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
- News
Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M
- Press releasePRNewswire
Oramed Reports Fiscal Third Quarter 2025 Financial Results
- Press releasePRNewswire
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
- Press releasePRNewswire
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
- Press releasePRNewswire
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
- News
Oramed Pharmaceuticals Issues Letter To Shareholders From President And CEO Nadav Kidron
- Press releasePRNewswire
Oramed Pharmaceuticals Issues Letter to Shareholders
- Press releasePRNewswire
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
- Press releasePRNewswire
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.